- Savient Pharmaceuticals (SVNT) files voluntary Chapter 11 petitions.
- The company is pursuing a sale under Section 363, with "stalking horse" bidder Sloan Holdings set to acquire Savient's assets for about $55M.
- The Sloan deal sets a floor price for a court-supervised auction.
- The assets in particular include Krystexxa, Savient's uric acid-specific enzyme indicated to treat chronic gout.
From other sites
at MarketWatch.com (Sep 25, 2012)
at CNBC.com (Sep 19, 2012)
at MarketWatch.com (Jul 11, 2012)
at MarketWatch.com (May 9, 2012)
at MarketWatch.com (Feb 1, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs